- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02589938
Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer (ACUPUNCTURE)
A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer
Study Overview
Status
Conditions
Detailed Description
Patients who have met all eligibility criteria will be randomized to standard oral hygiene, standard oral hygiene + true acupuncture twice weekly for 4 weeks, or standard oral hygiene + sham acupuncture twice weekly for 4 weeks by a form of adaptive randomization, called minimization, because simple randomization could result in covariate imbalances .
The acupuncture points will be at three sites on each ear (Shenmen, Point Zero, Salivary Gland 2-prime), a site on the chin (CV24), a site on each forearm (Lu7), a site on each hand (LI 1-prime), a site on each leg (K6), and one placebo needle at Gb32 for a total of 14 sites. All sites will be applied for 20 minutes. For body points, standardized techniques for location will be utilized, which are based on anatomical landmarks as well as proportional measurements using the patient's own body. For example, finger breadth is based on each patient's middle finger, and the proportional unit of measure, the "cun," is defined as the distance between the two medial ends of the creases of the interphalangeal joints when the middle finger is flexed. Earpoint locations will mimic standard practice and be identified by the acupuncturists.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Burbank, California, United States, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
San Francisco, California, United States, 94115
- Kaiser Permanente-San Francisco
-
San Jose, California, United States, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Rafael, California, United States, 94903
- Kaiser San Rafael-Gallinas
-
San Rafael, California, United States, 94903
- Kaiser Permanente-San Rafael
-
Santa Clara, California, United States, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Rosa, California, United States, 95403
- Kaiser Permanente-Santa Rosa
-
South San Francisco, California, United States, 94080
- Kaiser Permanente-South San Francisco
-
Walnut Creek, California, United States, 94596
- Kaiser Permanente-Walnut Creek
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, United States, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, United States, 96813
- University of Hawaii Cancer Center
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- John H Stroger Jr Hospital of Cook County
-
-
Iowa
-
Cedar Rapids, Iowa, United States, 52402
- Saint Luke's Hospital
-
Cedar Rapids, Iowa, United States, 52402
- Physicians' Clinic of Iowa PC
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Spectrum Health at Butterworth Campus
-
Grand Rapids, Michigan, United States, 49503
- Mercy Health Saint Mary's
-
-
Minnesota
-
Coon Rapids, Minnesota, United States, 55433
- Mercy Hospital
-
Edina, Minnesota, United States, 55435
- Fairview Southdale Hospital
-
Minneapolis, Minnesota, United States, 55415
- Hennepin County Medical Center
-
Saint Louis Park, Minnesota, United States, 55416
- Park Nicollet Clinic - Saint Louis Park
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- University of New Mexico Cancer Center
-
Santa Fe, New Mexico, United States, 87505
- Christus Saint Vincent Regional Cancer Center
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Chillicothe, Ohio, United States, 45601
- Adena Regional Medical Center
-
Columbus, Ohio, United States, 43214
- Columbus Oncology and Hematology Associates Inc
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Portland Medical Center
-
-
South Carolina
-
Boiling Springs, South Carolina, United States, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Greenville, South Carolina, United States, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, United States, 29605
- Prisma Health Greenville Memorial Hospital
-
Seneca, South Carolina, United States, 29672
- Prisma Health Cancer Institute - Seneca
-
-
Tennessee
-
Nashville, Tennessee, United States, 37208
- Meharry Medical College
-
-
Texas
-
Conroe, Texas, United States, 77384
- MD Anderson in The Woodlands
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
Houston, Texas, United States, 77079
- MD Anderson West Houston
-
-
Washington
-
Lacey, Washington, United States, 98503
- Providence Regional Cancer System-Lacey
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be at least 18 years of age and able to give informed consent.
- Must be able to read, write and understand English.
- Must have a diagnosis of head/neck cancer.
Must have received bilateral radiation therapy, and subsequently developed grade 2 or 3 xerostomia, according to modified RTOG scale:
- Grade 0 - None
- Grade 1 - Slight dryness of mouth (good response on stimulation and no significant dietary alterations necessary)
- Grade 2 - Moderate dryness of mouth (poor response on stimulation and altered oral intake required such as frequent water, oral lubricants, or soft-moist foods)
- Grade 3 - Complete dryness of mouth (no response on stimulation and difficult oral alimentation; IV fluids, pureed diet or tube feedings may be required)
- Grade 4 - Fibrosis
- Must have received external beam radiation at a mean dose of at least 24 Gy to one of the parotid glands. The other gland can receive less than 24 Gy.
- Must have completed radiotherapy at least 12 months prior to entry.
- Must have anatomically intact parotid and submandibular glands. A focused (head/neck) history and exam conducted by a physician or dentist within the past year is required.
- Must be acupuncture naïve.
- Must have ECOG performance status of 0-2.
Exclusion Criteria:
- History of xerostomia, Sjogren's disease or other illness known to affect salivation prior to head/neck radiation.
- Suspected or known closure of salivary gland ducts on either side. (Patients addressed in inclusion criteria (i.e. those who have had one submandibular gland removed) are expected to have closure to the removed submandibular gland and will be exempt from this exclusion criteria.)
- Currently receiving or planning to use drugs, herbs, alternative medicines, or devices that could affect salivary production. Treatment known to affect salivation should be stopped at least 14 days prior to enrollment. Over the counter products used for salivary substitution are allowed, but will need to be discontinued for at least 24 hours prior to saliva and questionnaire data collection.
- Have received any investigational new drug within the past 30 days or planning to receive such during the study period.
- Active systemic infection or skin infection at or near the acupuncture sites.
- Receiving chemotherapy during study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Standard Oral Hygiene
All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice.
Each participating site determines the standard oral hygiene recommendations used at their site.
|
Oral hygiene care provided per individual institutions standard of care.
Other Names:
|
EXPERIMENTAL: Standard Oral Hygiene + True Acupuncture
All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site. The True acupuncture points will be at 3 sites on each ear, a site on the chin, on each forearm, a site on each hand, a site on each leg, and one placebo needle for a total of 14 sites. All sites will be applied for 20 minutes. |
Oral hygiene care provided per individual institutions standard of care.
14 true acupoint sites will be selected and applied to each participant for 20 minutes at each session.
There will be 2 sessions a week for 8 weeks.
|
OTHER: Standard Oral Hygiene + Sham Acupuncture
All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site. The Sham acupuncture points will be given according to the same schedule as the active acupuncture points, except the Sham needles will be placed below, above or between true active points. |
Oral hygiene care provided per individual institutions standard of care.
14 sham acupoint sites will be selected and applied to each participant for 20 minutes at each session.
There will be 2 sessions a week for 8 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
9 Item Xerostomia Questionnaire
Time Frame: Baseline to 4 weeks post acupuncture
|
Self reported Xerostomia questionnaire completed prior to study randomization.
Each item is scored on a scale of 0-10 with higher scores indicating greater dryness or discomfort due to dryness, yielding a total between 0 and 90.
|
Baseline to 4 weeks post acupuncture
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response to a maximum of 6 months
Time Frame: Baseline to 6 Months
|
Duration of response assessed by determining Xerostomia Questionnaire scores at 8 and 12 weeks and the 6 month follow-up.
|
Baseline to 6 Months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Suzanne C Danhauer, PhD, Wake Forest University Health Sciences
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00038707
- REBAWF 97115 (OTHER: NCI)
- NCI-2011-02073 (REGISTRY: NCI CTRP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
Clinical Trials on Standard Oral Hygiene
-
National University Hospital, SingaporeRecruitingPeriodontal Diseases | Plaque Induced Gingival DiseaseSingapore
-
University of PennsylvaniaMedical University of South Carolina; NYU Langone Health; National Institute... and other collaboratorsTerminatedHead and Neck Cancer | Oral MucositisUnited States
-
University of Mississippi Medical CenterCompletedEsophageal Cancer | Lung CancerUnited States
-
Koite Health OyUniversity of Helsinki; Hammaslääkärit Eteläranta 10Not yet recruitingDental Implants | OsteolysisFinland
-
Koite Health OyKarolinska Institutet; University of HelsinkiWithdrawnPlaque | Inflamed Gums | Dryness OralSweden
-
Koite Health OyUniversity of Helsinki; University of OuluRecruitingPeriodontitis | Periodontal Diseases | Plaque Induced Gingivitis | Plaque, DentalFinland
-
University of California, IrvineLivionex IncCompletedPeriodontitis | Gingivitis | Dental PlaqueUnited States
-
Azienda Ospedaliera Città della Salute e della...Recruiting
-
University of BaghdadNot yet recruitingElectronic Cigarette Use | Plaque Induced Gingivitis
-
Boston Medical CenterUniversity of Alabama at BirminghamNot yet recruitingLow-grade Oral DysplasiaUnited States